St. Pete?s Alkor Bio extends drug allergen portfolio

St. Pete?s Alkor Bio extends drug allergen portfolioBiotech company Alkor Bio, a St. Petersburg-based developer and maker of reagents for lab diagnostics, earlier this month began production of its nine new drug allergens.

Biotech company Alkor Bio, a St. Petersburg-based developer and maker of reagents for lab diagnostics, has announced that in May, its allergology labs transferred into production nine new drug allergens, bringing the firm?s total of new developed allergens to 30 in one month alone. The group of the new 30 developed allergens includes the following categories: professional, epithelial, food-borne, mite allergens, insect poisons, as well as compound allergen formulae including a pediatric food-borne one. At the moment, companies operating under the Alkor Bio management umbrella, have a total of 212 ready-for-use allergens, including the rBetv1 recombinant birch pollen allergen. According to Lyudmila Kochish, the head of the allergology lab at Vega (part of the Alkor Bio group), ??our portfolio will have an additional new set of food-borne compounds, including fruit-borne and pollen mixtures, as well as formulae that comprise household dust allergens, such as fungal, mite and home-borne ones...